TY - JOUR
T1 - Incidence of single-drug resistant, multidrug-resistant and extensively drug-resistant Escherichia coli urinary tract infections
T2 - An Australian laboratory-based retrospective study
AU - Fasugba, Oyebola
AU - Das, Anindita
AU - Mnatzaganian, George
AU - Mitchell, Brett G.
AU - Collignon, Peter
AU - Gardner, Anne
N1 - Publisher Copyright:
© 2018 International Society for Chemotherapy of Infection and Cancer
PY - 2019/3
Y1 - 2019/3
N2 - Objectives: The aim of this study was to evaluate the incidence of single-drug resistant, multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) Escherichia coli urinary tract infections (UTIs) in a sample of Australian Capital Territory (ACT) residents. Methods: Laboratory-based retrospective data from all ACT residents whose urine samples were processed from January 2009 to December 2013 at ACT Pathology were utilised. Multivariate logistic regression models were constructed to determine the associations of age, sex, urine sample source and socioeconomic status with risk of resistant infections. Results: A total of 146 915 urine samples from 57 837 ACT residents were identified over 5 years. The mean ± standard deviation age of residents at first sample submitted was 48 ± 26 years, and 64.4% were female. The 5-year incidence of single-drug resistant E. coli UTI was high for ampicillin, trimethoprim and cefazolin (6.8%, 3.5% and 1.9%, respectively). No PDR E. coli UTI was detected. Five-year incidences of MDR and XDR E. coli UTIs were 1.9% and 0.2%, respectively, which is low in comparison with international rates. Female sex and age ≥38 years were significantly associated with single-drug and multidrug resistance. The risk of single-drug resistance was significantly higher in samples from after-hours general practice (GP) clinics compared with hospitals, office-hours GP clinics, and community and specialist health services (adjusted odds ratio = 2.6, 95% confidence interval 2.2–3.1). Conclusions: These findings have significant implications for antimicrobial prescribing given the identified risk factors for the detection of resistance, especially in patients attending after-hours GP clinics.
AB - Objectives: The aim of this study was to evaluate the incidence of single-drug resistant, multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) Escherichia coli urinary tract infections (UTIs) in a sample of Australian Capital Territory (ACT) residents. Methods: Laboratory-based retrospective data from all ACT residents whose urine samples were processed from January 2009 to December 2013 at ACT Pathology were utilised. Multivariate logistic regression models were constructed to determine the associations of age, sex, urine sample source and socioeconomic status with risk of resistant infections. Results: A total of 146 915 urine samples from 57 837 ACT residents were identified over 5 years. The mean ± standard deviation age of residents at first sample submitted was 48 ± 26 years, and 64.4% were female. The 5-year incidence of single-drug resistant E. coli UTI was high for ampicillin, trimethoprim and cefazolin (6.8%, 3.5% and 1.9%, respectively). No PDR E. coli UTI was detected. Five-year incidences of MDR and XDR E. coli UTIs were 1.9% and 0.2%, respectively, which is low in comparison with international rates. Female sex and age ≥38 years were significantly associated with single-drug and multidrug resistance. The risk of single-drug resistance was significantly higher in samples from after-hours general practice (GP) clinics compared with hospitals, office-hours GP clinics, and community and specialist health services (adjusted odds ratio = 2.6, 95% confidence interval 2.2–3.1). Conclusions: These findings have significant implications for antimicrobial prescribing given the identified risk factors for the detection of resistance, especially in patients attending after-hours GP clinics.
KW - Antimicrobial resistance
KW - Escherichia coli
KW - Incidence
KW - Urinary tract infection
UR - http://www.scopus.com/inward/record.url?scp=85062277142&partnerID=8YFLogxK
U2 - 10.1016/j.jgar.2018.10.026
DO - 10.1016/j.jgar.2018.10.026
M3 - Article
SN - 2213-7165
VL - 16
SP - 254
EP - 259
JO - Journal of Global Antimicrobial Resistance
JF - Journal of Global Antimicrobial Resistance
ER -